Aytu BioScience Company Insiders
| AYTU Stock | USD 2.37 0.01 0.42% |
Aytu BioScience employs about 102 people. The company is managed by 10 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 10.2 employees per reported executive. Breaking down Aytu BioScience's management performance can provide insight into the firm performance.
| Joshua Disbrow CEO CEO, Director |
Aytu BioScience's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Aytu BioScience's future performance. Based on our forecasts, it is anticipated that Aytu will maintain a workforce of slightly above 100 employees by August 2025.Aytu BioScience Management Team Effectiveness
Return On Tangible Assets is likely to drop to -1.53 in 2025. Return On Capital Employed is likely to gain to -1.02 in 2025. At this time, Aytu BioScience's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 142.6 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 4.9 M in 2025. Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to gain to about 6.7 M in 2025, whereas Net Loss is likely to drop (16.1 M) in 2025.
Aytu BioScience Workforce Comparison
Aytu BioScience is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 321. Aytu BioScience totals roughly 102 in number of employees claiming about 32% of equities under Health Care industry.
Aytu BioScience Profit Margins
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.0 | 28.5714 |
|
|
Aytu BioScience Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aytu BioScience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 1.5 | 3 | 2 | 15,314 | 314.00 |
| 2024-12-01 | 9.0 | 9 | 1 | 72,208 | 208.00 |
| 2024-09-01 | 1.0 | 1 | 1 | 209.00 | 209.00 |
| 2024-06-01 | 1.0 | 2 | 2 | 815,425 | 815,425 |
| 2024-03-01 | 1.0 | 1 | 1 | 208.00 | 208.00 |
| 2023-12-01 | 1.0 | 1 | 1 | 209.00 | 209.00 |
| 2023-09-01 | 12.0 | 12 | 1 | 83,208 | 208.00 |
| 2023-06-01 | 2.0 | 4 | 2 | 27,041 | 1,041 |
| 2022-12-01 | 0.6 | 6 | 10 | 836,371 | 532,819 |
| 2021-03-01 | 1.0 | 3 | 3 | 55,000 | 0.00 |
| 2020-06-01 | 2.8 | 14 | 5 | 15,895,845 | 15,007,543 |
| 2020-03-01 | 1.2 | 12 | 10 | 13,655,853 | 23,514,440 |
| 2019-12-01 | 10.0 | 10 | 1 | 2,884,936 | 0.00 |
| 2019-03-01 | 1.0 | 3 | 3 | 70,000 | 4,007,165 |
| 2018-12-01 | 8.0 | 8 | 1 | 1,700,500 | 3,330 |
| 2017-03-01 | 1.4706 | 25 | 17 | 1,541,668 | 1,219,583 |
| 2016-09-01 | 3.125 | 25 | 8 | 1,394,543 | 224,586 |
| 2016-06-01 | 8.0 | 8 | 1 | 11,200,000 | 45,000 |
| 2015-12-01 | 5.0 | 5 | 1 | 1,775,000 | 10,399,661 |
Aytu BioScience Notable Stakeholders
An Aytu BioScience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aytu BioScience often face trade-offs trying to please all of them. Aytu BioScience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aytu BioScience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Disbrow | CEO, Director | Profile | |
| Mark CPA | Secretary CFO | Profile | |
| Jarrett Disbrow | COO, Director | Profile | |
| Russ McMahen | Senior Development | Profile | |
| Christopher Brooke | Chief Officer | Profile | |
| Margaret Cabano | Vice Operations | Profile | |
| Topher Brooke | Chief Officer | Profile | |
| Greg Pyszczymuka | Chief Officer | Profile | |
| Ryan CPA | Executive Optimization | Profile | |
| Victoria Cordova | Vice Culture | Profile |
About Aytu BioScience Management Performance
The success or failure of an entity such as Aytu BioScience often depends on how effective the management is. Aytu BioScience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aytu management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aytu management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.46) | (1.53) | |
| Return On Capital Employed | (1.07) | (1.02) | |
| Return On Assets | (0.46) | (0.49) | |
| Return On Equity | (1.04) | (1.09) |
Please note, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Check Aytu BioScience's Beneish M Score to see the likelihood of Aytu BioScience's management manipulating its earnings.
Aytu BioScience Workforce Analysis
Traditionally, organizations such as Aytu BioScience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aytu BioScience within its industry.Aytu BioScience Manpower Efficiency
Return on Aytu BioScience Manpower
| Revenue Per Employee | 794.1K | |
| Revenue Per Executive | 8.1M | |
| Net Loss Per Employee | 155.3K | |
| Net Loss Per Executive | 1.6M |
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.